Literature DB >> 2180499

Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization.

H Yagura1, T Tamaki, T Furitsu, Y Tomiyama, T Nishiura, N Tominaga, S Katagiri, T Yonezawa, S Tarui.   

Abstract

Functional and structural characteristics of interleukin 2 (IL-2) receptors on B-cell chronic lymphocytic leukemia (B-CLL) cells were analyzed by a proliferation assay, IL-2 binding assay and cross-linking study. In the 3H-thymidine incorporation assay, purified B-CLL cells from four out of sixteen cases, in which the percentage of Tac antigen (Tac Ag) positive cells in peripheral blood lymphocytes ranged from 0 to 48.8%, responded to IL-2 (100 U/ml) after both 3- and 6-day incubation. No relationship was found between the responsiveness to IL-2 and the percentage of Tac Ag positive cells. In the radiolabeled IL-2 binding assay, however, B-CLL cells from all seven cases examined, including three cases with mitogenic response to IL-2 and four cases without mitogenic response, were shown to have both high- and low-affinity receptors. The number of high- and low-affinity receptors per cell ranged from 29-186 and from 420 to 1,800, respectively. Furthermore, with the affinity cross-linking method p55 (Tac Ag) and p70/75 were found even in cases without mitogenic response in their B-CLL cells. In conclusion, the B-CLL cells so far examined possessed high-affinity IL-2 receptors consisting of p55 and p70/75; nevertheless, this was not sufficient to respond to the mitogenic signal of IL-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180499     DOI: 10.1007/BF01720273

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  31 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Differential effects of interleukin 2 vs B cell growth factor on human B cells.

Authors:  T Nakagawa; N Nakagawa; J L Ambrus; A S Fauci
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

3.  Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal.

Authors:  S Karray; H Merle-Béral; A Vazquez; J P Gerard; P Debre; P Galanaud
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

4.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

6.  The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors.

Authors:  I Touw; L Dorssers; B Löwenberg
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

7.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

8.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

9.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Interleukin 2-induced proliferation of leukemic human B cells.

Authors:  O Lantz; C Grillot-Courvalin; C Schmitt; J P Fermand; J C Brouet
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

Review 4.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.